image
Healthcare - Biotechnology - NASDAQ - US
$ 4.25
10.7 %
$ 329 M
Market Cap
-1.41
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLDB stock under the worst case scenario is HIDDEN Compared to the current market price of 4.25 USD, Solid Biosciences Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLDB stock under the base case scenario is HIDDEN Compared to the current market price of 4.25 USD, Solid Biosciences Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLDB stock under the best case scenario is HIDDEN Compared to the current market price of 4.25 USD, Solid Biosciences Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SLDB

image
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-130 M OPERATING INCOME
-24.36%
-125 M NET INCOME
-29.87%
-100 M OPERATING CASH FLOW
-6.19%
-16.1 M INVESTING CASH FLOW
-166.02%
122 M FINANCING CASH FLOW
3821.75%
0 REVENUE
0.00%
-40.1 M OPERATING INCOME
-0.39%
-39.3 M NET INCOME
7.78%
-31.8 M OPERATING CASH FLOW
-7.44%
-27.5 M INVESTING CASH FLOW
-71.21%
190 M FINANCING CASH FLOW
2633.83%
Balance Sheet Solid Biosciences Inc.
image
Current Assets 157 M
Cash & Short-Term Investments 149 M
Receivables 0
Other Current Assets 8.38 M
Non-Current Assets 31.4 M
Long-Term Investments 0
PP&E 29 M
Other Non-Current Assets 2.32 M
78.93 %4.44 %15.39 %Total Assets$188.7m
Current Liabilities 30.3 M
Accounts Payable 4.24 M
Short-Term Debt 6.04 M
Other Current Liabilities 20 M
Non-Current Liabilities 21.2 M
Long-Term Debt 42.3 M
Other Non-Current Liabilities -21.2 M
8.24 %11.74 %38.87 %82.31 %Total Liabilities$51.4m
EFFICIENCY
Earnings Waterfall Solid Biosciences Inc.
image
Revenue 0
Cost Of Revenue 2.46 M
Gross Profit 0
Operating Expenses 130 M
Operating Income -130 M
Other Expenses -5.03 M
Net Income -125 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)0(2m)0(130m)(130m)5m(125m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-90.86% ROE
-90.86%
-66.10% ROA
-66.10%
-78.89% ROIC
-78.89%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Solid Biosciences Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -125 M
Depreciation & Amortization 2.46 M
Capital Expenditures -654 K
Stock-Based Compensation 10.5 M
Change in Working Capital 2.85 M
Others 9.51 M
Free Cash Flow -101 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Solid Biosciences Inc.
image
Wall Street analysts predict an average 1-year price target for SLDB of $16.4 , with forecasts ranging from a low of $12 to a high of $20 .
SLDB Lowest Price Target Wall Street Target
12 USD 182.35%
SLDB Average Price Target Wall Street Target
16.4 USD 285.88%
SLDB Highest Price Target Wall Street Target
20 USD 370.59%
Price
Max Price Target
Min Price Target
Average Price Target
20201818161614141212101088664422Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Solid Biosciences Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
143 K USD 7
6-9 MONTHS
151 K USD 5
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
26.1 M USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (“RSUs”) to two newly hired employees. globenewswire.com - 2 weeks ago
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D. globenewswire.com - 2 weeks ago
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - Duchenne (SGT-003) : Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT (SGT-501): FDA IND on track for submission first half of 2025 - - Cash: Company ended first quarter 2025 with $306.9 million in cash, cash equivalents, investments and available-for-sale securities; Solid has anticipated cash runway into the first half of 2027 - CHARLESTOWN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision, next generation, genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. globenewswire.com - 1 month ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees. globenewswire.com - 1 month ago
Solid Biosciences to Participate at The Citizens Life Sciences Conference CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET. globenewswire.com - 1 month ago
Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), from May 13-17, 2025, in New Orleans, LA. globenewswire.com - 1 month ago
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich's ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects. seekingalpha.com - 2 months ago
Can Solid Biosciences Challenge Sarepta in the DMD Market? When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease. marketbeat.com - 2 months ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted stock units (“RSUs”) to three newly hired employees. globenewswire.com - 2 months ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies. nypost.com - 2 months ago
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Dallas, TX, March 16-19, 2025. globenewswire.com - 3 months ago
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 3 months ago
8. Profile Summary

Solid Biosciences Inc. SLDB

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 329 M
Dividend Yield 0.00%
Description Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Contact 141 Portland Street, Cambridge, MA, 02139 https://www.solidbio.com
IPO Date Jan. 26, 2018
Employees 100
Officers Dr. Gabriel Brooks M.D. Chief Medical Officer Mr. David Tyronne Howton Jr., J.D. Chief Operating Officer & Secretary Mr. Alexander G. Cumbo President, Chief Executive Officer & Director Mr. Kevin Tan C.F.A. Chief Financial Officer & Treasurer Ms. Nicole Anderson Director of Investor Relations & Corporate Communications Ms. Allison Bogosian J.D. Senior Vice President of Human Resources Mr. Ilan Ganot Co-founder, Strategic Advisor to the Chief Executive Officer & Director Mr. Paul Herzich Chief Technology Officer Mr. Ian F. Smith A.C.A., C.P.A. Executive Chair Ms. Annie Ganot Co-Founder & Vice President of Patient Advocacy